This Catalog allows practitioners to consider which interventions have more robust evidence bases to support their practical application, such as: enhancing worker and supervisor competencies through training, offering nonfinancial incentives for high performers, practicing task sharing to promote cost savings, implementing digital solutions to expand access to services, and reducing costs of procuring and distributing pharmaceutical products.

To advance progress toward universal health coverage, agreed-upon health priorities need to be reflected in national plans and budgets. This blog offers key lessons for ministries of health seeking to make that happen.

This Question-and-Answer (Q&A) document covers commonly asked questions and answers on TB exams, treatment, and reimbursement through Social Health Insurance (SHI). It provides guidance to TB treatment facilities as they integrate SHI and transition TB treatment services into SHI. The document also includes hyperlinks as additional reference sources for readers.

This learning resource presents key learning from the activity literature review, learning exchange meetings, and TA workshops. This resource focuses particularly on stakeholder engagement and institutionalizing stronger links between national health priorities, sector plans and national budgets, which learning partners identified as their most pressing issues.

This two-pager focuses on USAID’s Learning Question 2, “What conditions or factors successfully facilitate the institutionalization and/or implementation at scale of good practices that improve health system outcomes, and why? What are lessons learned regarding planning for sustainability and achieving results at scale?”

Infographic describes seven lessons learned in Colombia while prioritizing health system strengthening during the COVID-19 pandemic.

The Vietnam government transitions funding of TB treatment to the SHI fund with support from LHSS. This transition marks a critical milestone, ensuring uninterrupted access to life-saving treatment.

Vietnam is one of the 30 countries with the highest burden of TB and drug-resistant TB in the world, with more than 172,000 cases and 10,400 deaths from TB in Vietnam in 2020 (WHO).  On July 1, TB treatment facilities nationwide started providing TB drugs to patients through social health insurance, marking an important milestone for financial sustainability.

This rapid assessment aimed to determine which health facilities in seven high-TB burden provinces of Vietnam meet social health insurance (SHI) requirements for TB service provision and for reimbursement of TB services through the SHI scheme.

Lhss prepared this report, discussing procurement and payment considerations related to the transition of first-line tuberculosis (TB) drug procurement in Vietnam from the central state budget to the social health insurance fund starting in 2022.

This document provides a roadmap for Vietnam’s National Tuberculosis (TB) Program to transition procurement and payment for TB drugs to the country’s social health insurance scheme.

This report discusses current processes for continuing professional development within the Ministry of Health’s Directorate for Licensing Professionals and Health Institutions and other stakeholder organizations.

This webinar discussed integrating social determinants of health approaches in health workforce education and practice. 

For the first time, Vietnam has procured TB medicines using its national social health insurance scheme. 

This video captures a November 6, 2020 ceremony in Hanoi which marked the formal start of the LHSS Project’s four-year effort to help the Government of Vietnam implement its social health insurance program. The program covers treatment services for people with HIV, among other essential health services.

Working closely with the Vietnam Social Security (VSS) agency, LHSS will help improve the agency’s capacity to manage the insurance program funds effectively, efficiently, equitably, and with accountability. LHSS will also support Vietnam’s transition to full financial ownership of its HIV and TB responses.